Oncology News | pharmaphorum

News

Gilead's Kite takes control of CAR-T partner Tmunity

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

News

Atara claims first world approval for off-the-shelf T-cell t...

Atara Biotherapeutics has become the first biotech to win regulatory approval for a T-cell therapy based on donated cells, rather than relying on cells harvested from patients and processed

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ's Imfinzi/Imjudo combo backed in EU for liver, lung cance...

AstraZeneca's oncology portfolio continues to deliver, with a recommendation for EU approval of its new Imfinzi/Imjudo immunotherapy combination heading a flurry of regulatory updates.

News

FDA approves Adstiladrin as first gene therapy for NMIBC

The US Food and Drug Administration (FDA) has

News

Second phase 3 trial extends Astellas' lead in claudin 18.2 ...

Astellas has confirmed it is out in front among developers of drugs targeting claudin 18.2, after a second phase 3 trial of zolbetuximab hit its objectives.

Gilead's Kite takes control of CAR-T partner Tmunity

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Atara claims first world approval for off-the-shelf T-cell t...

AZ's Imfinzi/Imjudo combo backed in EU for liver, lung cance...

FDA approves Adstiladrin as first gene therapy for NMIBC

Second phase 3 trial extends Astellas' lead in claudin 18.2 ...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks